Disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Neuland Laboratories Ltd has submitted the disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 199213-05-2014
13-05-2014
Results Press Release
Neuland Laboratories Ltd has submitted to BSE a copy of Results Press Release for the period ended March 31, 2014.09-05-2014
Board recommends Dividend
Neuland Laboratories Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 09, 2014, inter alia, have recommended payment of dividend of 30% (including a special dividend of 15%) at Rs. 3 per equity share on a face value of Rs. 10 each, subject to the approval of members of the Company.09-05-2014
Financial Results for March 31, 2014 (Audited)
Neuland Laboratories Ltd about the Financial Results for the period ended March 31, 2014.09-05-2014
Board to consider Dividend
Neuland Laboratories Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on May 09, 2014, inter-alia to consider and take on record the audited financial results of the Company for the year ended March 31, 2014 and to consider and recommend dividend, if any.Further the Company has informed that, as per the provisions of the Code of Conduct for Prevention of Insider Trading of the Company, the Trading...28-04-2014
Neuland Labs Inaugurates new manufacturing facility constructed for its Collaboration with Mitsubishi Healthcare Unit API Corporation
Neuland Laboratories Ltd has informed BSE regarding a Press Release dated April 08, 2014, titled "Neuland Labs Inaugurates new manufacturing facility constructed for its Collaboration with Mitsubishi Healthcare Unit API Corporation."09-04-2014
Shareholding Pattern for March 31, 2014
Neuland Laboratories Ltd has informed BSE about the Shareholding Pattern for the Quarter ended March 31, 2014.08-04-2014
Published notice of submission of Draft Letter of Offer to SEBI
Neuland Laboratories Ltd has submitted to BSE a copy of newspaper publication of the notice of submitting the Draft Letter of Offer with the Securities and Exchange Board of India, which was published on March 28, 2014.28-03-2014
Outcome of Board Meeting
Neuland Laboratories Ltd has informed BSE that the Board of Directors of the Company at its meeting held on March 20, 2014, had approved re-appointment of Dr. D. R. Rao as the Chairman and Managing Director of the Company, for a further period of 5 years w.e.f. April 01, 2014, subject to the approval of the shareholders.20-03-2014